LIVN - LivaNova PLC Stock Price, Fair Value and News

62.06USD+0.11 (+0.18%)Market Closed

Market Summary

USD62.06+0.11

Market Closed

0.18%

LIVN Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

LIVN Stock Price

View Fullscreen

LIVN RSI Chart

LIVN Valuation

Market Cap

3.4B

Price/Earnings (Trailing)

-105.6

Price/Sales (Trailing)

2.83

EV/EBITDA

-85.41

Price/Free Cashflow

110.19

LIVN Price/Sales (Trailing)

LIVN Profitability

EBT Margin

-10.56%

Return on Equity

-2.6%

Return on Assets

-1.29%

Free Cashflow Yield

0.91%

LIVN Fundamentals

LIVN Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

11.96%

Rev. Growth (Qtr)

-4.91%

LIVN Earnings

Earnings (TTM)

-31.8M

Earnings Growth (Yr)

-669.1%

Earnings Growth (Qtr)

-356.7%

Breaking Down LIVN Revenue

52 Week Range

43.6362.55

(Low)(High)

Last 7 days

-1.6%

Last 30 days

10.9%

Last 90 days

22.6%

Trailing 12 Months

31.9%

How does LIVN drawdown profile look like?

LIVN Financial Health

Current Ratio

3.17

Debt/Equity

0.5

Debt/Cashflow

0.11

LIVN Investor Care

Shares Dilution (1Y)

0.71%

Diluted EPS (TTM)

-0.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2B	0	0	0
2023	1.0B	1.1B	1.1B	1.2B
2022	1.0B	1.0B	1.0B	1.0B
2021	939.4M	1.0B	1.0B	1.0B
2020	1.1B	980.8M	952.3M	934.2M
2019	1.1B	1.1B	1.1B	1.1B
2018	1.0B	1.1B	1.1B	1.1B
2017	782.5M	799.8M	983.6M	1.0B
2016	640.9M	811.4M	982.4M	782.7M
2015	253.7M	255.8M	263.4M	294.7M
2014	275.1M	282.0M	285.1M	288.5M
2013	0	254.3M	261.2M	268.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of LivaNova PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 30, 2024	shvartsburg alex	sold (taxes)	-352,981	55.94	-6,310	cfo
Mar 30, 2024	bolton stephanie	sold (taxes)	-203,789	55.94	-3,643	president, global epilepsy
Mar 30, 2024	hutchinson michael damon	acquired	-	-	1,478	chief legal officer
Mar 30, 2024	shvartsburg alex	acquired	-	-	14,752	cfo
Mar 30, 2024	hutchinson michael damon	sold (taxes)	-30,319	55.94	-542	chief legal officer
Mar 30, 2024	hebbelinck trui	sold (taxes)	-309,964	55.94	-5,541	chief human resources officer
Mar 30, 2024	hebbelinck trui	acquired	-	-	11,779	chief human resources officer
Mar 30, 2024	bolton stephanie	acquired	-	-	7,744	president, global epilepsy
Feb 29, 2024	kozy william a	acquired	-	-	14,512	chairman and ceo
Feb 29, 2024	kozy william a	sold (taxes)	-266,980	54.81	-4,871	chairman and ceo

Which funds bought or sold LIVN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Edgestream Partners, L.P.	sold off	-100	-1,086,590	-	-%
May 10, 2024	Pacer Advisors, Inc.	reduced	-0.86	30,113	449,310	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	126	199,212	336,478	-%
May 10, 2024	VANGUARD GROUP INC	added	3.53	10,931,300	102,537,000	-%
May 10, 2024	Liontrust Investment Partners LLP	unchanged	-	31,736	422,683	0.01%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-51.43	-52,273	57,842	-%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	new	-	239,367	239,367	0.02%
May 10, 2024	GROUP ONE TRADING, L.P.	new	-	4,196	4,196	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	new	-	94,000	94,000	-%
May 10, 2024	Jackson Creek Investment Advisors LLC	sold off	-100	-894,000	-	-%

Are Funds Buying or Selling LIVN?

Are funds buying LIVN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LIVN

No. of Funds

Unveiling LivaNova PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 17, 2024	integrated core strategies (us) llc	5.1%	2,733,440	SC 13G
Feb 12, 2024	primecap management co/ca/	10.75%	5,791,280	SC 13G/A
Jan 23, 2024	blackrock inc.	13.8%	7,415,557	SC 13G/A
May 09, 2023	primecap management co/ca/	10.07%	5,394,100	SC 13G/A
Feb 14, 2023	harris associates l p	3.8%	2,008,159	SC 13G/A
Feb 09, 2023	primecap management co/ca/	8.58%	4,594,917	SC 13G/A
Jan 26, 2023	blackrock inc.	12.8%	6,834,335	SC 13G/A
Jan 20, 2023	blackrock inc.	12.8%	6,834,335	SC 13G/A
Feb 11, 2022	harris associates l p	7.2%	3,823,266	SC 13G/A
Feb 10, 2022	primecap management co/ca/	8.3%	4,415,445	SC 13G/A

Recent SEC filings of LivaNova PLC

View All Filings

Date Filed	Form Type	Document
May 03, 2024	10-Q	Quarterly Report
May 03, 2024	IRANNOTICE	IRANNOTICE
May 01, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 17, 2024	SC 13G	Major Ownership Report
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to LivaNova PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.1B	40.3B	-6.91%	-5.44%	32.37	4.52	-2.84%	-3.08%
BDX	67.9B	19.7B	-4.40%	-6.39%	50.95	3.44	4.82%	-17.56%
ALGN	21.1B	3.9B	-15.05%	-8.09%	45.66	5.39	5.72%	46.72%
BAX	18.3B	14.9B	-16.06%	-18.00%	6.92	1.23	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	6.22%	24.59%	31.58	2.79	6.16%	35.06%
HSIC	9.4B	12.5B	0.31%	-3.70%	24.24	0.76	-0.61%	-18.83%
BIO	7.9B	2.6B	-18.28%	-24.14%	-24.53	3.04	-6.25%	-68.62%
XRAY	5.9B	3.9B	-14.09%	-31.22%	-62.62	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.49%	17.89%	-215.82	8.88	30.82%	65.57%
PDCO	2.4B	6.6B	-0.94%	-	12.18	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-11.83%	-17.09%	-1.76	0.38	7.94%	-1661.78%
ANIK	374.6M	169.3M	-2.43%	-	-4.88	2.21	7.49%	-244.90%
ANGO	245.1M	324.0M	-12.34%	-33.15%	-1.27	0.76	-3.19%	-337.41%
APYX	57.5M	50.5M	17.69%	-50.29%	-2.52	1.14	14.25%	-10.06%
AEMD	3.1M	3.7M	-28.92%	247.06%	-0.25	0.82	5.77%	8.23%

LivaNova PLC News

Latest updates

LivaNova PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.9%	295	310	286	294	263	275	253	254	240	270	253	264	248	270	240	182	242	288	269	277	251
Gross Profit	9.1%	207	190	202	205	174	184	171	184	168	202	169	172	163	167	148	115	165	193	-	-	-
S&GA Expenses	-2.6%	130	133	135	126	124	120	115	116	119	124	109	123	116	117	104	103	120	153	123	127	126
R&D Expenses	-1.1%	46.00	46.00	47.00	51.00	50.00	45.00	36.00	34.00	41.00	44.00	42.00	53.00	45.00	44.00	47.00	25.00	36.00	23.00	46.00	35.00	44.00
EBITDA Margin	-1712.2%	-0.03*	0.00*	0.09*	-0.01*	0.01*	0.00*	-0.02*	0.04*	-0.02*	-0.05*	-0.33*	-0.30*	-	-	-	-	-	-	-	-	-
Interest Expenses	1.7%	16.00	16.00	15.00	15.00	13.00	13.00	13.00	14.00	8.00	6.00	11.00	17.00	16.00	16.00	15.00	6.00	5.00	5.00	5.00	4.00	2.00
Income Taxes	107.0%	8.00	-110	5.00	4.00	2.00	5.00	1.00	3.00	3.00	3.00	2.00	4.00	3.00	-18.54	-3.99	66.00	-44.71	-6.94	-10.65	-6.16	-6.61
Earnings Before Taxes	63.7%	-34.20	-94.30	-1.98	5.00	10.00	6.00	-106	19.00	6.00	-2.30	-41.56	-52.54	-28.08	-301	-18.71	-21.66	-6.01	-152	21.00	-35.56	-21.46
EBT Margin	-50.0%	-0.11*	-0.07*	0.02*	-0.08*	-0.07*	-0.07*	-0.08*	-0.02*	-0.09*	-0.12*	-0.41*	-0.39*	-	-	-	-	-	-	-	-	-
Net Income	-356.7%	-41.94	16.00	-7.32	1.00	7.00	2.00	-107	16.00	3.00	-5.13	-43.44	-56.49	-30.76	-281	-14.81	-89.41	36.00	-143	32.00	-29.21	-14.85
Net Income Margin	-276.2%	-0.03*	0.02*	0.00*	-0.09*	-0.08*	-0.08*	-0.09*	-0.03*	-0.10*	-0.13*	-0.40*	-0.37*	-	-	-	-	-	-	-	-	-
Free Cashflow	-91.3%	4.00	41.00	9.00	-23.60	13.00	10.00	30.00	-16.37	21.00	26.00	21.00	19.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1.2%	2,460	2,430	2,329	2,342	2,295	2,295	2,213	2,336	2,417	2,201	2,203	2,397	2,369	2,400	2,522	2,503	2,454	2,412	2,510	2,622	2,600
Current Assets	5.2%	1,040	988	954	942	903	886	851	772	810	679	646	809	691	708	673	672	617	549	547	568	541
Cash Equivalents	131.0%	616	267	234	223	214	214	506	407	442	208	182	329	253	253	228	233	126	61.00	75.00	45.00	51.00
Inventory	3.6%	153	148	162	156	142	129	122	119	115	106	124	127	125	115	178	177	170	164	168	169	161
Net PPE	-1.3%	152	154	149	150	149	147	139	143	148	150	153	157	158	164	191	186	184	181	180	185	186
Goodwill	-1.4%	772	783	767	779	774	769	742	898	897	900	905	918	910	922	918	902	889	916	946	962	952
Liabilities	7.5%	1,238	1,152	1,104	1,101	1,068	1,087	1,066	1,054	1,125	906	891	1,356	1,303	1,291	1,171	1,169	1,062	1,028	1,015	1,138	1,113
Current Liabilities	-2.2%	328	335	295	288	316	297	288	264	308	697	658	702	295	309	282	268	530	513	469	596	622
Long Term Debt	6.4%	605	569	568	568	520	518	518	460	456	10.00	11.00	431	646	642	637	639	316	260	273	174	142
LT Debt, Current	9.1%	19.00	17.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.00
LT Debt, Non Current	-100.0%	-	569	568	568	520	518	518	460	456	10.00	11.00	431	646	642	637	639	316	260	273	174	142
Shareholder's Equity	-4.4%	1,222	1,278	1,225	1,241	1,227	1,208	1,147	1,282	1,292	1,295	1,299	1,029	1,055	1,109	1,351	1,333	1,393	1,378	1,495	1,483	1,487
Retained Earnings	-4.3%	-1,008	-966	-982	-975	-976	-984	-985	-878	-894	-897	-879	-837	-782	-761	-472	-457	-369	-406	-263	-295	-266
Additional Paid-In Capital	0.1%	2,193	2,190	2,181	2,169	2,163	2,158	2,144	2,133	2,121	2,118	2,107	1,779	1,770	1,768	1,758	1,751	1,740	1,735	1,725	1,717	1,707
Shares Outstanding	0.4%	54.00	54.00	54.00	54.00	54.00	54.00	53.00	53.00	53.00	51.00	52.00	49.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,800	-	-	-	3,300	-	-	-	4,100	-	-	-	2,300	-	-	-	3,500	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-81.5%	9,981	53,958	18,136	-17,937	20,757	18,703	35,638	-10,243	25,823	33,480	23,953	25,631	19,480	36,985	8,657	-19,019	-106,045	2,866	-76,587	-19,395	1,974
Share Based Compensation	23.5%	10,226	8,283	11,779	5,711	10,579	12,317	10,727	11,509	10,256	9,990	11,122	9,916	9,536	8,244	7,811	9,991	9,043	8,426	8,531	8,724	6,872
Cashflow From Investing	47.6%	-6,363	-12,138	-10,054	-6,655	-11,484	-10,953	-5,831	-16,148	-5,482	-3,631	-6,180	56,573	-9,858	-8,507	-10,671	-11,581	-11,085	-10,771	-8,065	-16,813	-5,641
Cashflow From Financing	840.3%	37,147	-5,018	-4,277	36,014	-5,235	-1,657	73,230	-6,320	214,877	-3,300	-164,096	-5,759	-8,328	-5,171	-3,770	136,604	183,093	-7,160	116,684	29,468	7,589
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LIVN Income Statement

2024-03-31

Condensed Consolidated Statements of (Loss) Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenue	$ 294,912	$ 263,418
Cost of sales	87,522	89,335
Gross profit	207,390	174,083
Operating expenses:
Selling, general and administrative	129,863	124,129
Research and development	45,664	49,986
Other operating expenses	15,617	2,310
Operating income (loss)	16,246	(2,342)
Interest expense	(15,893)	(13,437)
Loss on debt extinguishment	(25,482)	0
Foreign exchange and other income/(expense)	(9,071)	25,547
(Loss) income before tax	(34,200)	9,768
Income tax expense	7,717	2,371
Loss from equity method investments	(26)	(27)
Net (loss) income	$ (41,943)	$ 7,370
Basic (loss) income per share (in dollars per share)	$ (0.78)	$ 0.14
Diluted (loss) income per share (in dollars per share)	$ (0.78)	$ 0.14
Shares used in computing basic (loss) income per share (in shares)	54,008	53,617
Shares used in computing diluted (loss) income per share (in shares)	54,008	53,900

LIVN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 309,191	$ 266,504
Restricted cash	306,492	311,368
Accounts receivable, net of allowance of $11,026 at March 31, 2024 and $12,019 at December 31, 2023	209,431	215,072
Inventories	153,176	147,887
Prepaid and refundable taxes	22,543	20,145
Prepaid expenses and other current assets	39,184	27,182
Total Current Assets	1,040,017	988,158
Property, plant and equipment, net	152,237	154,181
Goodwill	771,817	782,941
Intangible assets, net	253,927	261,178
Operating lease assets	50,260	50,845
Investments	22,675	22,843
Deferred tax assets	113,687	118,858
Long-term derivative assets	41,617	38,496
Other assets	13,365	12,063
Total Assets	2,459,602	2,429,563
Current Liabilities:
Current debt obligations	19,704	18,111
Accounts payable	75,944	80,845
Accrued liabilities and other	94,029	107,301
Current litigation provision liability	16,980	10,756
Taxes payable	29,761	23,340
Accrued employee compensation and related benefits	91,353	94,630
Total Current Liabilities	327,771	334,983
Long-term debt obligations	604,753	568,543
Contingent consideration	80,769	80,902
Deferred tax liabilities	10,974	11,567
Long-term operating lease liabilities	43,724	45,388
Long-term employee compensation and related benefits	17,062	17,254
Long-term derivative liabilities	104,920	45,569
Other long-term liabilities	48,092	47,729
Total Liabilities	1,238,065	1,151,935
Commitments and Contingencies
Stockholders’ Equity:
Ordinary Shares, £1.00 par value: unlimited shares authorized; 54,295,837 shares issued and 54,148,808 shares outstanding at March 31, 2024; 53,942,151 shares issued and 53,918,222 shares outstanding at December 31, 2023	82,975	82,533
Additional paid-in capital	2,192,676	2,189,517
Accumulated other comprehensive loss	(45,206)	(27,883)
Accumulated deficit	(1,008,427)	(966,484)
Treasury stock at cost, 147,029 ordinary shares at March 31, 2024; 23,929 ordinary shares at December 31, 2023	(481)	(55)
Total Stockholders’ Equity	1,221,537	1,277,628
Total Liabilities and Stockholders’ Equity	$ 2,459,602	$ 2,429,563

About LivaNova PLC

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

CEO	Mr. William A. Kozy
WEBSITE	livanova.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2900

LivaNova PLC Frequently Asked Questions

What is the ticker symbol for LivaNova PLC? What does LIVN stand for in stocks?

LIVN is the stock ticker symbol of LivaNova PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LivaNova PLC (LIVN)?

As of Thu May 09 2024, market cap of LivaNova PLC is 3.35 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIVN stock?

You can check LIVN's fair value in chart for subscribers.

What is the fair value of LIVN stock?

You can check LIVN's fair value in chart for subscribers. The fair value of LivaNova PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LivaNova PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIVN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LivaNova PLC a good stock to buy?

The fair value guage provides a quick view whether LIVN is over valued or under valued. Whether LivaNova PLC is cheap or expensive depends on the assumptions which impact LivaNova PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIVN.

What is LivaNova PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, LIVN's PE ratio (Price to Earnings) is -105.6 and Price to Sales (PS) ratio is 2.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIVN PE ratio will change depending on the future growth rate expectations of investors.